Insulin-like growth factor-II (IGF-II) has been shown to promote pancreatic b-cell survival. We evaluated the effect of co-encapsulating islets and bioengineered IGF-II-producing cells on islet cell survival. IGF-II or green fast protein (GFP) genes were transferred into TM4 cells, and purified using a neomycin resistance gene, leading to pure cell cultures (TM4-IGF-II or TM4-GFP) with a stable overexpression of the transferred gene. Islets were co-encapsulated with TM4-IGF-II or TM4-GFP, or encapsulated alone in alginate microcapsules. Rat and mouse islet cell survival was studied in vitro and in vivo, respectively. After 12 days in culture, islet viability (dual staining, acridine orange/propidium iodide) was 83% with TM4-IGF-II, compared with 51% (Po0.05) and 41% (Po0.001) with TM4-GFP and islets alone, respectively. The study of islet necrotic centers and the evaluation of islet function, using the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) assay, yielded similar results. From 125 days after transplantation, more diabetic mice maintained normoglycemia when they were transplanted with islets co-encapsulated with TM4-IGF-II (4/7). A significant difference for the maintenance of normoglycemia was observed between recipients of islets co-encapsulated with TM4-IGF-II versus islets alone (P¼0.023), or with TM4-GFP (P¼0.048). In conclusion, the co-encapsulation of islets with bioengineered IGF-II-producing cells promotes islet cell survival.
INTRODUCTION
The transplantation of islets of Langerhans (islets) has induced insulin independence and considerably improved the blood glucose control in patients with type 1 diabetes. 1 However, follow-up studies have shown a 90% recurrence of insulin dependence at 5 years post transplantation; the median duration of insulin independence was 15 months (interquartile range 6.2-25.5). 2, 3 The limited duration of insulin independence emphasizes the need to develop methods that promote islet cell survival. Here, we provide direct evidence that b-cell survival can be improved by co-encapsulating islets and bioengineered cells that stably overexpress the insulin-like growth factor-II (IGF-II) gene.
Rosenberg et al. 4 have demonstrated in vitro that incubations of hamster islets with duct cells, duct cell conditioned medium (which was shown to contain mainly IGF-II) or IGF-II alone decrease islet cell apoptosis and necrosis that occur in the immediate (48 h) post-islet isolation period. 5 We have investigated the use of IGF-II in a transplantation setting. 6 In vitro studies showed that IGF-II prevents the apoptosis and necrosis of microencapsulated mouse islet cells in a dose-dependent manner. In a marginal islet mass transplantation model, pre-transplantation IGF-II incubations allowed prolonged blood glucose normalization in a higher proportion (B200%) of diabetic mice, using a reduced (50%) amount of islets. 6 Hill et al. 7 have previously found that the massive b-cell apoptosis that occurs in the neonatal period is prevented in transgenic mice overexpressing the IGF-II gene. The beneficial effect of pancreatic duct cells, which produce IGF-II, on islet cell survival has also been supported by the finding of a significant correlation between a higher percentage of duct cell contamination in islet preparations and a positive outcome of clinical transplantations. 8 The mechanisms underlying these observations are unknown. Such an association has not been found with any other components of the pancreas.
In our previous study, 6 islets were exposed to IGF-II for only 48 h in vitro, before being transplanted. Nonetheless, this procedure had a considerable impact on in vivo islet cell survival. We thus hypothesized that the continuous in vivo delivery of IGF-II to islets, after transplantation, would promote the long-term maintenance of the transplanted islet cell mass and function.
In preliminary studies (unpublished data), the IGF-I, IGF-II or IGF-I+II genes were transfected into islet cells. In these experiments, only a few cells per islet expressed the transgene. In spite of this limitation, in vitro islet cell survival was significantly improved. These results suggested that IGF, which is secreted locally by a limited number of cells, may have a positive paracrine effect on neighboring cells. To prolong IGF supply to islets, we investigated another strategy. Bioengineered TM4 cells stably overexpressing the IGF-I, IGF-II or IGF-I+II genes (TM4-IGF-I, II or I+II cells) were co-encapsulated with islets within alginate microcapsules. This procedure significantly improved in vitro and in vivo islet cell survival. In these preliminary experiments, the effect of IGF-II was somewhat stronger than that of IGF-I, and there was no additive effect of IGF-I plus IGF-II. In the present paper, we report the results of in vitro and in vivo experiments of the co-encapsulation of islets with bioengineered IGF-II-producing cells.
RESULTS

Establishment and characterization of a mouse IGF-II-producing TM4 cell line (TM4-IGF-II)
The cDNA sequence of mouse IGF-II in pIRES vector was analyzed in an independent laboratory and showed a high homology with the published sequence. 9 The percentage of homology in sense was 95% (437/458), and in antisense 96% (446/464), that is less than 0.5% error of the 542 bases after merging the two sequences. Geneticin-resistant clones were selected for both pIRES-IGF-II and pIRES-GFP (pIRESgreen fast protein) expression. These clones were able to grow in the basal medium after 3 weeks of selection in G418 (Geneticin, Invitrogen Life Technologies Inc., Burlington, Ontario, Canada). The observation of GFP-transfected TM4 cells showed that only a few cells were positive on fluorescence microscopy 48 h after transfection, whereas all cells were positive after selection (data not shown). TM4-IGF-II clones at 3 weeks showed recombinant mouse IGF-II gene expression confirmed by RT-PCR. Electrophoresis of the IGF-II DNA product by reverse transcription of mRNA extract from TM4-IGF-II clone cells showed the same size of DNA as the positive control near 600 bp ( Figure 1 ). Qualitative protein secretion in the supernatant was analyzed by Dot Blot, when they were probed with the anti-mouse IGF-II antibody. Densitometry analyses of IGF-II on Dot Blot showed a 2.02 ratio between TM4-IGF-II and TM4-wild type (TM4-wt), whereas TM4-wt cells showed no or negligible secretion at the detection limit of this technique ( Figure 2 ). In addition, the ratio TM4-IGF-II/positive control made with 100 ng of pure IGF-II protein was 1.06. With our culture conditions, the TM4-IGF-II cell product approximated 500 ng per ml of IGF-II. We proved, in TM4-IGF-II clones, the presence of IGF-II mRNA and the production of a secreted protein that was bound by an antibody against IGF-II.
Effect of encapsulated cells on microcapsule morphology
Microscopy was used to determine the efficiency of islet co-encapsulation with TM4 cells, and the homogeneity of the islets/TM4 cell distribution within microcapsules. At the cell concentration that was used, TM4 cells did not interfere with microcapsule morphology and size. In addition, the microcapsule morphology was similar for either condition (that is, islets encapsulated alone or co-encapsulated with TM4 cells) and reproducible for each experiment. Figure 3 shows a photomicrograph of an islet co-encapsulated with TM4 cells.
Biological effect of co-encapsulating islets with TM4-IGF-II cells on islet cell viability: in vitro study In order to test the hypothesis that co-encapsulating islets and TM4-IGF-II cells promotes islet cell survival, in vitro studies of islet viability and morphology were performed during 19 days in culture. After co-encapsulation, islets were cultured in CMRL 1066 supplemented with serum.
Morphology. No significant differences of islet morphology were observed during the first week. At day 12 post encapsulation, the microscopic examination showed a significantly lower percentage of islets with a necrotic center in islets co-encapsulated with TM4-IGF-II cells (58 ± 5.3%) than in control groups of islets encapsulated alone (77.2±6.5%; Po0.05) and islets co-encapsulated with TM4-GFP cells (71.8±5.1%; P¼0.05). For the three conditions, the average diameter of islets with a necrotic center was much larger than that of islets without necrotic centers. The average diameter of islets with necrotic centers was higher for islets co-encapsulated with TM4-IGF-II cells than that for controls. The diameter of the necrotic centers was smaller in islets co-encapsulated with TM4-IGF-II cells than in controls.
As expected, 10 the dual-staining fluorescence microscopy analysis showed that the viability of islets encapsulated alone decreased during the 19 days of culture and was severely reduced at day 12 ( Figure 4 ). In contrast, islets that were co-encapsulated with TM4-IGF-II cells had no increase in the number of dead cells at day 12 ( Figure 4 ). TM4-IGF-II cells significantly improved the percentage of viable encapsulated islet cells. There was no decrease in the viability of islets co-encapsulated with TM4-IGF-II cells during the first 12 days of culture, as opposed to the control groups, which showed a significant drop in islet cell viability ( Figure 4 ). Unexpectedly, in initial experiments (which were performed in CMRL 1066 culture medium), TM4-IGF-II cells seemed to lose their protective properties at around day 19 in culture, although the viability in this group was still better than that of the controls ( Figure 4) .
assay was performed at day 12 to assess cell viability. After normalization for islet size and formazan production by TM4 cells, islets that were co-encapsulated with TM4-IGF-II cells showed a significantly improved (146.1±14.9 AU) as compared with islets encapsulated alone (70.1 ± 23.6 AU) and those co-encapsulated with TM4-GFP (83.7 ± 17 AU) (data not shown).
Effect of different culture media on microencapsulated TM4 cell function In order to investigate the potential effect of the culture medium, the function of encapsulated TM4 cells cultured in CMRL 1066 was compared with that cultured in DMEM/F12. The results of the MTS assay confirmed the harmful effect of CMRL 1066 on TM4 cell function ( Figure 5 ). With both media, TM4 cells reacted to encapsulation by an initial decrease of function during the first day. With CMRL, a progressive drop of the formazan production was observed, leading to a total absence of formazan detection at day 20 and thereafter. In contrast, when DMEM/F12 was used, the production of formazan by the encapsulated TM4 cells increased rapidly and was maintained throughout the experiment. Moreover, the microscopic examination showed that the number and morphology of the encapsulated TM4 cells that were cultured in DMEM/F12 did not change during the study, as opposed to those cultured in CMRL, which presented considerable deterioration. These results demonstrate that CMRL is not an appropriate medium for long-term culture of TM4 cells. They also explain why, in the foregoing experiment, the protective effect of co-encapsulated TM4 cells on islet cell survival lasted less than 19 days. On the other hand, CMRL is known to be more supportive than DMEM/F12 of islet survival in culture. Although this experimental issue is related to long-term (that is 412 days) in vitro studies, it does not affect in vivo studies or clinical application. In the two latter cases, co-encapsulated islets and TM4 cells would be kept in culture for only 24 h before they are transplanted. In vivo studies are required to investigate the long-term effect (that is 412 days) of co-encapsulating islets and TM4-IGF-II cells on islet survival.
Effect of co-encapsulating islets and TM4-IGF-II cells on in vivo islet cell survival: islet transplantation study All of the experimental groups (that is, islets co-encapsulated with TM4-IGF-II or TM4-GFP, encapsulated alone, and not encapsulated) presented similar ratios of islets on islet equivalents (1.04±0.05; 1.20±0.10; 0.99±0.09, respectively). Therefore, islets of the same average size were used for each of the four groups. A minimal islet mass model was used: only 150 allogeneic islet equivalents were transplanted intraperitoneally into STZ-induced diabetic mice for each experimental group. This number of islets was based on our previous experiments. 6 When non-encapsulated islets were used, only two out of five recipients became normoglycemic, and they maintained this normoglycemia only for a period of 12 and 31 days, respectively. When islets encapsulated alone were transplanted, normoglycemia was induced in 71% (5/7) of the recipients ( Figure 6 ). However, progressive recurrence of hyperglycemia was observed, and only 28% (2/7) remained normoglycemic after 48 days and the maximum duration of normoglycemia was 84 days (Figure 6 ). A similar pattern was observed with islets co-encapsulated with TM4-GFP cells: the maximum duration of normoglycemia was 77 days. In contrast, when 150 islet equivalents co-encapsulated Figure 4 Quantitative assessment of islet viability using acridine orange and propidium iodide staining. Islets were cultured in CMRL medium for prolonged periods. The percentage of viable islets was evaluated under a fluorescence microscope. In white: islets alone, gray: islets with TM4-GFP, black: islets with TM4-IGF-II. Experiments were performed on seven islet preparations for days 1, 6, 12, and on 3 islet preparations for day 19. Each preparation was analyzed by two blinded observers. Data are presented as mean±s.e.m. *Po0.05; **Po0.01 and ***Po0.001. Co-encapsulation of bioengineered cells and islets G Jourdan et al with TM4-IGF-II cells were used, 100% (7/7) of diabetic mice normalized their blood glucose, 100% (7/7) remained normoglycemic at 20 days and 57% (4/7) during 125 days ( Figure 6 ). In the TM4-IGF-II group, the longer duration of normoglycemia was 233 days (the recipient was still normoglycemic when it was euthanized) compared with 77 days and 84 days in the TM4-GFP and the islet encapsulated alone groups, respectively. A significant difference between recipients of islets co-encapsulated with TM4-IGF-II and islets encapsulated alone persisted during 94 days ( Figure 6 ).
DISCUSSION
The results of the present study demonstrate that in vivo continuous supply of IGF-II to transplanted islets improves b-cell survival. This was achieved by co-encapsulating islets and TM4 cells stably overexpressing the IGF-II gene (TM4-IGF-II). Both in vitro and in vivo studies showed that islets that were co-encapsulated with TM4-IGF-II cells presented significantly improved survival over islets microencapsulated alone or co-encapsulated with TM4 cells that were not transfected with the IGF-II gene (TM4-GFP). This positive effect was due to the co-encapsulated IGF-II-producing cells and could not be explained by the immunoprotection offered by the microcapsules because (1) in vitro, there is no immune reaction of the host; (2) in vivo, an immuno-incompetent animal model (scid mice) was used as recipient; (3) our study included the appropriate control, that is, islets co-encapsulated with TM4 cells that were not transfected with the IGF-II gene; although a slightly positive effect was observed, it was clearly and significantly smaller than that with islets co-encapsulated with TM4-IGF-II cells.
The TM4-IGF-II cells were developed using a nonviral vector and the DOTAP method, by in vitro transfer of a plasmid comprising the IGF-II gene and a neomycin resistance gene, followed by cell selection using incubations in a neomycin analog. In spite of a relatively low transfection rate, 11 this strategy allowed the production of a pure culture of cells presenting a stable expression of the IGF-II gene. In recent years, safe and more efficient vectors have been developed. [12] [13] [14] The strategy of the present work could be used while taking advantage of the continuous progress in vector development. The advantages of the DOTAP system include its proven safety and the fact that it can be used in a standard laboratory.
The simple approach that is described in the present report presents a number of advantages. The paracrine effect of IGF-II allows to improve b-cell viability by transferring the IGF-II gene into cells other than the b-cells; this enabled to select and expand the TM4-IGF-II cells in culture, which led to the production of a pure culture of cells stably overexpressing the IGF-II gene. This was possible because a monocellular cell culture was used. As the islet is a well-differentiated and organized multicellular structure, comprising approximately 2000-3000 cells, this approach is not feasible by gene transfer directly into islet cells. Moreover, this approach is not possible using genes that have an intracellular action on cell viability; for example, those inhibiting or stimulating pro-apoptotic or anti-apoptotic signaling pathways, respectively, or affecting the intracellular production of free radicals. The modulation of the expression of these genes can protect only the cells that have been transfected and not the neighboring cells. Therefore, co-encapsulating islets with cells overexpressing these genes would have no effect on islet survival. Even within an islet, nontransfected cells would not be protected.
We have selected TM4 cells because it is a non-malignant cell line that has the intracellular machinery for hormone storage and secretion. Moreover, these cells have the capacity to replicate but present contact inhibition. In preliminary experiments, certain immortalized cell lines, such as Chinese hamster ovary cells, could overexpand and sometimes break microcapsules. Such a phenomenon did not occur with TM4 cells. TM4 cells are derived from Sertoli cells, which have an immune-modulating function in preventing immune destruction of spermatozoa. If TM4 cells keep these features, an additional advantage might be protecting islets and/or microcapsules against an immune reaction. This possibility has not been evaluated by the present study, because in vitro there is no immune reaction and in vivo an immunoincompetent animal model was used, precisely to avoid potential confounding immunological factors. Therefore, the absence of a significant protective effect by TM4-GFP cells was not unexpected. Moreover, the mechanism of the immunomodulating effect of Sertoli cells has been at least partly attributed to Fas/Fas ligand binding. It is unlikely that this mechanism plays a role in the case of encapsulated cells, as the capsule membrane would prevent Fas/Fas ligand contact. If soluble factors are involved, then such an effect is possible. Additional experiments in an immunocompetent animal model would be required to address this issue.
A pitfall in our initial in vitro studies was the fact that the survival of TM4-IGF-II cells was limited when they were cultured for several days in CMRL, which is the preferred culture medium for islets. This phenomenon does not affect the results of in vivo studies and eventual clinical applications, as co-encapsulated islets/TM4-IGF-II cells would be kept in culture only approximately 24 h before transplantation. The in vitro studies of co-encapsulated islets/TM4-IGF-II cells that were cultured in CMRL showed a protective effect that was parallel to the time course of TM4-IGF-II cell survival in the same culture medium. This provides further support to our conclusion that TM4-IGF-II cell promotes islet cell survival.
The strategy that was used in the present study can be applied using other peptides that have a paracrine protective effect on islet cell survival. Examples of such peptides include hepatocyte growth factor, [15] [16] [17] calcitonin gene-related peptide 18 and nerve growth factor. 19 Using adenoviral vectors, Narang et al. 20 have shown that ex-vivo transfection of two genes that target different islet insults has an additive effect on transplanted islet cell survival, as compared with the transfection of either gene alone. Therefore, it is conceivable that the strategy that was used in the present work is applied using cells that are transfected with two or more different genes, or combining two or several types of cells overexpressing different genes. Other research groups have experimented gene transfer with the aim of controlling the autoimmune reaction against islets. [21] [22] [23] [24] [25] [26] [27] [28] Considering the limited duration of insulin independence in recipients of islet transplantation, an important area of research is to design methods to promote islet survival. The mere immobilization of islets in alginate beads has been shown to improve islet survival both in vitro and in vivo. The next logical step is to identify and remove deleterious factors that are involved in the islet isolation and encapsulation techniques. 29 Other methods are designed to improve oxygen supply to encapsuled islet cells. 30, 31 Therefore, the method that is proposed in the present paper should be seen as one component of a more general strategy to improve islet cell survival.
In conclusion, the results of this work confirm that co-encapsulating islets with IGF-II-producing bioengineered cells has a positive effect on islet cell survival.
MATERIALS AND METHODS Animals
Islets that were isolated from male Wistar rats (250-400 g body weight; Charles River Inc., St Constant, Québec, Canada) were used for in vitro study. For in vivo studies, islets were isolated from B6.CB17 mice (Charles River Inc.), and transplanted into B6.CB17-Prkdc scid/SzJ mice (15-20 g body weight; The Jackson Laboratory, Bar Harbor, ME, USA). Protocols were reviewed by the animal care and ethics committee of Maisonneuve-Rosemont Hospital Research Centre, and were confirmed to comply with the guidelines of the CCAC. These guidelines were observed throughout the study.
Plasmid pIRES/CMV-mouse IGF-II
IGF-II mRNA was extracted from fresh mouse liver cells, using TRIzol reagent (Invitrogen Life Technologies Inc.). IGF-II cDNA were generated by RT-PCR on IGF-II mRNA using superScrip II Reverse Transcriptase (Invitrogen Life Technologies Inc.), and IGF-II cDNA amplification was performed by PCR using Pfx polymerase (Invitrogen Life Technologies Inc.). Mouse IGF-II cDNA was sequenced and compared with published mouse IGF-II DNA sequence 9 to confirm its homology (see Results). Mouse IGF-II cDNA was inserted into an NheI/NotI digested pIRES/CMV for eukaryotic expression. The neomycin and the ampicillin resistance genes were used for selection in mammalian cells and Escherichia coli, respectively.
TM4-IGF-II and TM4-GFP cell lines
TM4 cells were obtained from ATCC (American Type Culture Collection, Manassas, VA, USA; ATCC number CRL 1715), and maintained in a basal culture medium consisting of Ham F12/Dulbecco's modified Eagle's medium (1:1 mixture) (Gibco, Invitrogen Life Technologies Inc.), 5% horse serum, 2.5% fetal bovine serum, 0.5 mM sodium pyruvate, 1.2 g per litre sodium bicarbonate and 1% penicillin-streptomycin 100Â solution (Invitrogen Life Technologies Inc.) at 37 1C in humidified air atmosphere containing 5% CO 2 . Adherent cells, at 50% confluence in a 35-mm 2 Petri dish, were transfected by the liposome method using 3 mg DNA in 18ml transfection reagent DOTAP (Roche Molecular Biochemicals, Laval, Québec, Canada) for 8 h in the absence of serum and antibiotics. The cells were then renewed with basal culture medium for 24 h, before the addition of 400 mg Geneticin per ml (G418, Invitrogen Life Technologies Inc.) for the selection of the neomycin-resistant cells. From this point, resistant clones were cultured for an additional 3 weeks in the presence of G418. At 3 weeks, the cells were removed from their culture medium for IGF-II expression analysis and were cryopreserved in basal medium supplemented with 5% DMSO. For each experiment, control cultures were performed using cells transfected with the vector only or pIRES-GFP plasmid or without any gene transfection. The media and transfected cells were collected and screened at different times from 48 h to 30 days after transfection.
Screening of TM4-IGF-II cell lines
Detection of recombinant protein was performed by immunoblot on culture medium. The media of different cells (TM4-IGF-II, TM4-GFP and wild type) were cultured for 24 h, blotted onto a nitrocellulose blotting membrane (Pall Canada Ltd, Ville St-Laurent, Québec, Canada), and subjected to immunodetection, using a polyclonal antiserum against rat IGF-II (cross-reactivity against mouse IGF-II, but not mouse IGF-I) (1:1000, Cedarlane laboratories, Hornby, British Columbia, Canada) and indirect detection using an ECL western blotting analysis system (Amersham Biosciences, Little Chalfont, England). The positive control was made with 100 ng of pure IGF-II proteins added to 200 ml of medium for TM4 cell culture. Each analysis was made with 200 ml to exclude a volume bias.
RT-PCR on TM4-IGF-II
mRNA was extracted by TRIzol reagent according to the manufacturer's protocol (Invitrogen Life Technologies Inc.) from TM4-IGF-II and TM4 wild-type cells. The RT-PCR products were analyzed, using standard electrophoresis on 1% agarose gel and compared with pIRES-IGF-II PCR.
Islet isolation
Islets were isolated and purified from rat and mouse pancreases, according to a previously described procedure. 32 Rat islets were used for in vitro studies, because of the large number of islets that was required, and the fact that rat islet isolation is less labor-intensive than mouse islet isolation. Mouse islets were used for in vivo transplantation studies in mouse recipients, because an allogeneic, rather than xenogeneic, transplantation model enabled focusing on islet cell survival, while avoiding potential immunological confounding factors. Briefly, pancreases were infused via the common bile duct with 20 ml of type V collagenase (1 g per liter in Hanks' balanced salt solution; Sigma-Aldrich Ltd, Oakville, Ontario, Canada), set apart, and kept on ice. Digestion was performed for 30 min at 37 1C. Islets were purified on discontinuous Euroficoll gradient (Mediatech Inc., Herndon, VA, USA), handpicked under an inverted light microscope, pooled, and then separated to form four experimental groups: islets co-encapsulated with TM4-IGF-II or TM4-GFP cells, encapsulated alone, and not encapsulated. Islets were cultured overnight in RPMI 1640 medium (Invitrogen Life Technologies Inc.) with 11 mM glucose supplemented with 10% fetal bovine serum (Invitrogen Life Technologies Inc.), 1% penicillinstreptomycin-glutamine 100Â solution (Invitrogen Life Technologies Inc.), in humidified air atmosphere containing 5% CO 2 .
Islet microencapsulation and co-encapsulation TM4-IGF-II and TM4-GFP cells were thawed and cultured in DMEM/F12 supplemented by serum, 5 days before use. Islets were microencapsulated (alone or co-encapsulated with TM4-IGF-II or TM4-GFP) in purified UPLVG alginate (PRONOVA Biomedical AS, Oslo, Norway) under endotoxin-free conditions. Islets were mixed with 1.3% UPLVG alginate at a final concentration of 5000 islets per ml. For co-encapsulation, islets were mixed with TM4-GFP or TM4-IGF-II cells at a final concentration of 1000 islets for 20 million TM4 cells, before being mixed with alginate. Islets, alone or with TM4 cells, were entrapped in small alginate beads by extrusion of the alginate solution through a 25-gauge needle using an electrostatic pulse generator. 33 The alginate Co-encapsulation of bioengineered cells and islets G Jourdan et al beads fell into a 100-mM calcium lactate solution, which cross-linked the alginate to form calcium alginate-gelled beads. This procedure was performed at room temperature. For in vitro experiments, islets encapsulated alone or coencapsulated with TM4-GFP or TM4-IGF-II cells (microcapsule diameter: 300-350 mm) were cultured for an additional 19 days in CMRL medium with 10% fetal bovine serum, 1% penicillin-streptomycin-glutamine 100Â solution at 37 1C and in humidified air atmosphere containing 5% CO 2 In vitro studies using prolonged times in culture were designed to evaluate the potential protective effect of islet co-encapsulation with TM4-IGF-II cells. The culture medium was changed every second day as previously described. 5 Note that, for in vivo experiments, the time in culture (in CMRL) was limited to 2 days, the islets being transplanted 24 h after encapsulation and 48 h after isolation, which corresponds to what would be done in clinical applications. TM4-IGF-II and TM4-GFP cells were cultured in DMEM/F12 supplemented by serum until co-encapsulation with islets, then cultured for 24 h in CMRL until transplantation. Figure 3 shows islets that are co-encapsulated with TM4-IGF-II cells.
Microencapsulated islet morphology
Inverted light microscopy. Aliquots of 100 islets per experimental condition were studied under an inverted microscope. Islet diameter (micrometers) and the diameter (micrometers) of the area of necrosis were measured using a calibrated scale mounted on the microscope eyepiece. The number of encapsulated or co-encapsulated islets with central necrosis was expressed as the percentage of the total islet number, as previously described. 5 Microencapsulated islet and TM4 cell viability and function: in vitro study Fluorescence microscopy. Fluorescence microscopy was used, as previously described, 34 to evaluate islet cell viability at the end of the incubation periods. In brief, aliquots of 100 microencapsulated islets were stained with propidium iodide (0.5 mg ml À1 ; Sigma-Aldrich) and acridine orange (2.4 ng ml À1 ; SigmaAldrich), which stain dead and living cells, respectively. The number of microencapsulated islets showing more than 60% viable cells were counted and expressed as a percentage of the total. Two blinded experimenters analyzed each aliquot.
MTS assay. The functions of encapsulated TM4 cells and encapsulated or co-encapsulated islets were analyzed by the MTS assay using cell Titer96 (Promega, Madison, WI, USA). Encapsulated cells and/or islets (100 beads) were incubated in the respective basal medium for TM4 cells or HBSScontaining MTS salt, in a 96-well plate for 4 h in a humidified air atmosphere containing 5% CO 2 . MTS is metabolized by the mitochondria of viable cells to soluble formazan, which was detected using an ELISA plate reader (absorbency wavelength: 450 nm; reference wavelength: 620 nm). The results are expressed in arbitrary units of absorbance (AU). The formazan product was normalized for 150 islet equivalents and the presence of co-encapsulated TM4 cells. Controls included TM4 cells from the same preparation that were immobilized in alginate beads without islets. The amount of formazan that was produced by these cells was subtracted from the results obtained with islets that were co-encapsulated with TM4 cells. 35 
Microencapsulated islet transplantation and in vivo islet survival
Recipients. Diabetes was induced in mice by intraperitoneal injection of streptozotocin (STZ; 185 mg per kg body weight in sodium citrate buffer, pH 4.5; Sigma-Aldrich). The blood glucose levels of all mice rose above 20 mM within 2 days post injection of STZ. Daily s.c. Ultralente insulin injections were used to maintain the mice living (Humulin U, 2 U/day, Eli Lilly, Toronto, Ontario, Canada). Ten days after injection of STZ, diabetic mice (blood glucose 420 mM for 2 days) were used as recipients of microencapsulated or co-encapsulated islet transplantation. Control groups included diabetic mice transplanted with islets encapsulated alone, co-encapsulated with TM4-GFP cells and non-encapsulated islets.
Transplantation. After islet isolation, the islet preparation was carefully and uniformly suspended, and split into four equal aliquots, which were randomly assigned to four experimental groups: islets co-encapsulated with TM4-IGF-II, co-encapsulated with TM4-GFP, encapsulated alone and not encapsulated.
After overnight culture in RPMI 1640 medium (Invitrogen Life Technologies Inc.) with 11 mM glucose supplemented with 10% fetal bovine serum (Invitrogen Life Technologies Inc.), 1% penicillin-streptomycin-glutamine 100Â solution (Invitrogen Life Technologies Inc.) in humidified air atmosphere containing 5% CO 2 , islets were mixed or not with TM4-IGF-II or TM4-GFP cells just before microencapsulation. Encapsulated and co-encapsulated islets were cultured 24 h before transplantation. Immediately before transplantation, islets from the four experimental groups were counted to obtain aliquots of 150 islet equivalents, using a calibrated scale mounted in the eye piece of a microscope. Encapsulated or co-encapsulated islet aliquots were transplanted via a 16-gauge catheter into the peritoneal cavity of diabetic mice anaesthetized with sodium pentobarbital (Somnotol, 50 mg per kg body weight; MTC Pharmaceutical, Cambridge, Ontario, Canada). The last insulin injection was given at the time of transplantation to minimize the hyperglycemic stress, to which islets would be submitted during the initial hours post transplantation.
Follow-up of diabetic mice following transplantation
Recipient mice had free access to water and food (mouse colony chow 5018; Agrigrands, Purina, Ontario, Canada). Blood glucose levels were measured on blood samples obtained from the tail veins (glucometer Accu-Chek Advantage, Roche Diagnostics, Québec, Canada) every 2 days during the first week post transplantation, and then at least once a week for the remainder of the study. Mice were considered normoglycemic when blood glucose levels were less than 11 mM on two consecutive measures. In order to avoid bias supporting our hypothesis, a mouse that died while normoglycemic was considered diabetic at the time of death (one in the TM4-IGF-II group at day 233).
Statistical analysis
All in vitro experiments were performed six times, and the results are expressed as mean±s.e.m. The difference between experimental groups was analyzed by unpaired Student's t-test, with Po0.05 considered significant. The differences between experimental groups within a category were analyzed by Fisher's test, with Po0.05 considered significant.
